1
|
Baross Á, Delaney AD, Li HI, Nayar T, Flibotte S, Qian H, Chan SY, Asano J, Ally A, Cao M, Birch P, Brown-John M, Fernandes N, Go A, Kennedy G, Langlois S, Eydoux P, Friedman JM, Marra MA. Assessment of algorithms for high throughput detection of genomic copy number variation in oligonucleotide microarray data. BMC Bioinformatics 2007; 8:368. [PMID: 17910767 PMCID: PMC2148068 DOI: 10.1186/1471-2105-8-368] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2006] [Accepted: 10/02/2007] [Indexed: 01/22/2023] Open
Abstract
Background Genomic deletions and duplications are important in the pathogenesis of diseases, such as cancer and mental retardation, and have recently been shown to occur frequently in unaffected individuals as polymorphisms. Affymetrix GeneChip whole genome sampling analysis (WGSA) combined with 100 K single nucleotide polymorphism (SNP) genotyping arrays is one of several microarray-based approaches that are now being used to detect such structural genomic changes. The popularity of this technology and its associated open source data format have resulted in the development of an increasing number of software packages for the analysis of copy number changes using these SNP arrays. Results We evaluated four publicly available software packages for high throughput copy number analysis using synthetic and empirical 100 K SNP array data sets, the latter obtained from 107 mental retardation (MR) patients and their unaffected parents and siblings. We evaluated the software with regards to overall suitability for high-throughput 100 K SNP array data analysis, as well as effectiveness of normalization, scaling with various reference sets and feature extraction, as well as true and false positive rates of genomic copy number variant (CNV) detection. Conclusion We observed considerable variation among the numbers and types of candidate CNVs detected by different analysis approaches, and found that multiple programs were needed to find all real aberrations in our test set. The frequency of false positive deletions was substantial, but could be greatly reduced by using the SNP genotype information to confirm loss of heterozygosity.
Collapse
Affiliation(s)
- Ágnes Baross
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
- Genome British Columbia, 500-555 West 8th Avenue, Vancouver, BC, V5Z 1C6, Canada
| | - Allen D Delaney
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - H Irene Li
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Tarun Nayar
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Stephane Flibotte
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Hong Qian
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Susanna Y Chan
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Jennifer Asano
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Adrian Ally
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Manqiu Cao
- Affymetrix Inc., 3420 Central Expressway, Santa Clara, CA 95051, USA
| | - Patricia Birch
- Dept. of Medical Genetics, University of British Columbia, Children's & Women's Hospital, Box 153, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada
| | - Mabel Brown-John
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Nicole Fernandes
- Dept. of Medical Genetics, University of British Columbia, Children's & Women's Hospital, Box 153, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada
| | - Anne Go
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
| | - Giulia Kennedy
- Affymetrix Inc., 3420 Central Expressway, Santa Clara, CA 95051, USA
| | - Sylvie Langlois
- Dept. of Medical Genetics, University of British Columbia, Children's & Women's Hospital, Box 153, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada
| | - Patrice Eydoux
- Dept. of Pathology and Laboratory Medicine, BC Children's Hospital,4480 Oak Street, Vancouver, BC, V6H 3N1, Canada
| | - JM Friedman
- Dept. of Medical Genetics, University of British Columbia, Children's & Women's Hospital, Box 153, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada
| | - Marco A Marra
- Genome Sciences Centre, BC Cancer Agency, British Columbia Cancer Agency, Suite 100, 570 West 7th Avenue, Vancouver, BC, V5Z 4S6, Canada
- Dept. of Medical Genetics, University of British Columbia, Children's & Women's Hospital, Box 153, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada
| |
Collapse
|